Drug interactions
Liposomal doxorubicin + Paclitaxel protein bound
Severity: Moderate
Liposomal doxorubicin and Paclitaxel protein bound: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Paclitaxel can reduce doxorubicin clearance, which may increase doxorubicin exposure and its toxicity, particularly with conventional formulations. Both drugs cause myelosuppression, and the combination may raise the risk of cardiotoxicity.
What this interaction means in plain words
Liposomal doxorubicin and Paclitaxel protein bound can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Paclitaxel may reduce doxorubicin clearance, possibly through effects on biliary excretion and P-glycoprotein.
What to do
Monitor blood counts and cardiac function, including LVEF, throughout therapy. Reduce doses if neutropenia or cardiac decline develops.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Liposomal doxorubicin and Paclitaxel protein bound, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Frequently asked questions
Can I take Liposomal doxorubicin with Paclitaxel protein bound?
MediHelp rates the interaction as moderate. Liposomal doxorubicin and Paclitaxel protein bound can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Paclitaxel can reduce doxorubicin clearance, which may increase doxorubicin exposure and its toxicity, particularly with conventional formulations. Both drugs cause myelosuppression, and the combination may raise the risk of cardiotoxicity.
How serious is the interaction between Liposomal doxorubicin and Paclitaxel protein bound?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function, including LVEF, throughout therapy. Reduce doses if neutropenia or cardiac decline develops.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
